What is Avicanna Inc. (AVCNF)?

Avicanna Inc. (AVCNF) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of AVCNF?

The current price of AVCNF is $0.08. Prices are updated in real time on Stocks360.

What is AVCNF's price-to-earnings (PE) ratio?

AVCNF's trailing twelve-month PE ratio is -3.09, based on current price and earnings per share data available on Stocks360.

What is AVCNF's market capitalization?

AVCNF's market capitalization is $10,078,789.00, placing it in the small-cap tier.

Avicanna Inc. (AVCNF)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$0.08

Market Cap

$10.08M

PE (TTM)

-3.09

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.33

Day Range

$0.07 – $0.08

52-wk Range

$0.06 – $0.20

Avg Volume

N/A

Volume

1.40K

Avicanna Inc. (AVCNF) is a publicly traded company in the Healthcare sector. Latest price: $0.08. Market cap $10.08M. Trailing PE -3.09. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 6 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $0.20 2026-10-29 · $0.08 (-61.54%)

Earnings

Most Recent

Aug 17, 2026

EPS $-0.01 vs est. $-0.03

Beat by $0.03

Next Earnings

Nov 13, 2026

EPS estimate $-0.03

Proprietary Signals

Signal snapshot temporarily unavailable.

About Avicanna Inc.

Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships with Canadian academic and medical institutions. Its scientific approach, encompassing robust R&D and clinical development, underpins the commercialization of roughly twenty products across four primary market segments. The company offers a diverse portfolio, including: RHO Phyto: Medical and wellness products containing cannabinoids such as CBD, CBG, and THC. Pura H&W and Pura Earth: Functional CBD-infused derma-cosmetic and topical products for consumers. Aureus: A range of cannabis and hemp-derived goods, including dried flowers, standardized seeds, full-spectrum extracts, cannabinoid distillates, isolated cannabinoids, and bulk formulations. Furthermore, Avicanna is developing pharmaceutical solutions targeting conditions such as epidermolysis bullosa, dermatological issues, chronic pain, and various neurological disorders. A notable research collaboration exists with Dr. Christine Allen's Research Group, investigating cannabinoid-based treatment…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-3.09×
P/S (TTM)	0.53×
P/B	2.74×
PEG	0.04×
P/FCF (TTM)	-4.00×
EV / EBITDA	-4.40×
EV / Sales	0.53×
Earnings Yield	-30.98%
Free Cash Flow Yield	-25.01%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$13.41M
Revenue (TTM)	$25.31M
Net Income (TTM)	-$4.16M
Free Cash Flow (TTM)	-$3.30M
Net Debt	-$30.85K
Working Capital	-$275.51K
Gross Margin	51.87%
Operating Margin	-14.76%
Net Margin	-15.45%
Return on Equity	-108.44%
Return on Invested Capital	-25.46%